bioAffinity Technologies (NASDAQ:BIAF) Stock Rating Upgraded by Wall Street Zen

bioAffinity Technologies (NASDAQ:BIAF) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Monday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

bioAffinity Technologies Stock Performance

Shares of bioAffinity Technologies stock opened at $0.66 on Friday. The firm has a market capitalization of $3.13 million, a P/E ratio of -0.06 and a beta of -1.11. The company has a quick ratio of 1.34, a current ratio of 1.36 and a debt-to-equity ratio of 0.15. The company has a 50 day moving average price of $1.14 and a 200 day moving average price of $1.69. bioAffinity Technologies has a 52 week low of $0.61 and a 52 week high of $13.50.

bioAffinity Technologies (NASDAQ:BIAF) last released its earnings results on Friday, May 8th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($2.40) by $1.59. The company had revenue of $1.35 million for the quarter, compared to the consensus estimate of $1.48 million. bioAffinity Technologies had a negative net margin of 280.53% and a negative return on equity of 285.75%.

Institutional Trading of bioAffinity Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in BIAF. J. Safra Sarasin Holding AG purchased a new position in shares of bioAffinity Technologies in the 1st quarter valued at about $164,000. Geode Capital Management LLC acquired a new position in shares of bioAffinity Technologies during the fourth quarter valued at approximately $36,000. Finally, Scientech Research LLC acquired a new stake in shares of bioAffinity Technologies in the third quarter worth approximately $49,000. Institutional investors and hedge funds own 1.64% of the company’s stock.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.